Abstract
This study looked at whether oral desmopressin, by decreasing kidney urine production, would prolong bladder filling-time thereby increasing the time to reach maximum capacity, thus reducing overactive bladder (OAB) symptoms, and providing an alternative method of treatment to OAB sufferers. An investigator-initiated, 2-week, multi-national, multi-centre, "proof-of-concept," phase IIb, double-blind, placebo-controlled, prospective, randomized, cross-over study was conducted using 0.2 mg of oral desmopressin in adults suffering with OAB. Patients were included in the trial period if they had >or=4 voids in the first 8-hr of the day after rising, excluding the first morning void. The primary endpoint was evaluation of effectiveness of desmopressin in increasing the time to the first OAB symptom episodes during the first 8-hr following treatment. Time to first void was 8-min later on the drug than on placebo (P = 0.27). However, the drug led to one less void (3.2 vs. 4.2) in the same period (P < 0.001). There was an increase in the time to first urgency episode with a decrease in the number of urgency episodes in the drug days compared to placebo (P < 0.003). There was a subjective improvement in frequency and urgency and overall ...Continue Reading
References
May 1, 1992·Annals of Neurology·G ValiquetteJ Herbert
Jan 1, 1990·Scandinavian Journal of Urology and Nephrology·A C Kinn, P O Larsson
Sep 1, 1983·Journal of Neurology, Neurosurgery, and Psychiatry·P HiltonS L Stanton
Jun 1, 1982·British Journal of Urology·P Hilton, S L Stanton
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·O SuchowerskyG Rohs
Jul 1, 1996·Acta Neurologica Scandinavica·S Fredrikson
Dec 1, 1996·Archives of Neurology·G ValiquetteP Maede-D'Alisera
Oct 6, 1997·British Journal of Obstetrics and Gynaecology·C J KelleherS Salvatore
May 8, 1999·BJU International·R AsplundP Bengtsson
May 8, 2000·The Journal of Urology·M M HassounaR A Schmidt
Feb 22, 2002·Neurourology and Urodynamics·Paul AbramsUNKNOWN Standardisation Sub-committee of the International Continence Society
May 16, 2002·BJU International·A MattiassonJ Weiss
Jul 13, 2002·American Journal of Obstetrics and Gynecology·Paul AbramsAlan Wein
Oct 2, 2002·Current Urology Reports·Michael GrossRodney A Appell
Oct 31, 2003·American Journal of Obstetrics and Gynecology·Gunnar LoseUNKNOWN Nocturia Study Group
May 15, 2004·BJU International·D RobinsonJ P Norgaard
Jul 12, 2005·The Journal of Urology·Annabel NixonNorman Zinner
Feb 14, 2006·The Journal of Urology·Paul AbramsUNKNOWN ICIQ Advisory Board
Feb 7, 2007·European Urology·Philip van KerrebroeckJens Peter Nørgaard
May 19, 2007·The Journal of Urology·Arun SahaiProkar Dasgupta
Dec 13, 2007·European Urology·Thomas M Kessler
Citations
Mar 2, 2010·Women's Health·Monika VijLinda Cardozo
Jun 3, 2015·BJU International·Raveen Syan, Benjamin M Brucker
Oct 13, 2015·BJU International·Vincent TseJeffrey Thavaseelan
Apr 14, 2010·Expert Opinion on Emerging Drugs·Monika VijLinda Cardozo
Nov 16, 2010·The Journal of Urology·Jeffrey P Weiss
May 27, 2009·The Journal of Urology·Omer Faruk Karatas
Feb 20, 2009·International Journal of Urology : Official Journal of the Japanese Urological Association·Tim SchneiderMartin C Michel
Jul 14, 2011·Korean journal of urology·Young Kook HanHayoung Kim
Nov 1, 2010·Female Pelvic Medicine & Reconstructive Surgery·Hashim Hashim, Paul Abrams
Oct 19, 2019·BJU International·Rachael D SussmanBenjamin M Brucker
Jun 7, 2011·Annals of Medicine·Ariana L Smith, Alan J Wein
May 22, 2020·Frontiers in Physiology·Eduardo M CafarchioMonica A Sato
Dec 12, 2020·Frontiers in Physiology·Monica A SatoRuss Chess-Williams
Mar 30, 2019·European Urology·Benoit PeyronnetJean-Nicolas Cornu
May 18, 2021·Expert Review of Clinical Pharmacology·Natasha Alford, Hashim Hashim
Jul 30, 2021·Frontiers in Physiology·Gustavo B LamyMonica A Sato